Morgan Stanley downgrades Bristol-Myers Squibb on drug pipeline concern

Uncertainty around drug developments could hold back the price of Bristol-Myers Squibb stock, according to Morgan Stanley.

Analyst David Risinger downgraded the stock to equal weight from overweight on Friday, saying the long-term picture for the company's earnings power was getting less positive.